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Abstract
MicroRNAs have been shown to function in cartilage devel-
opment and homeostasis, as well as in progression of osteo-
arthritis. The objective of the current study was to identify
microRNAs involved in the onset or early progression of os-
teoarthritis and characterise their function in chondrocytes.
MicroRNA expression in mouse knee joints post-DMM sur-
gery was measured over 7 days. Expression of miR-29b-3p
was increased at day 1 and regulated in the opposite direction
to its potential targets. In a mouse model of cartilage injury
and in end-stage human OA cartilage, the miR-29 family was
also regulated. SOX9 repressed expression ofmiR-29a-3p and
miR-29b-3p via the 29a/b1 promoter. TGFβ1 decreased ex-
pression of miR-29a, b, and c (3p) in primary chondrocytes,
whilst IL-1β increased (but LPS decreased) their expression.
The miR-29 family negatively regulated Smad, NFκB, and
canonical WNT signalling pathways. Expression profiles re-
vealed regulation of new WNT-related genes. Amongst these,
FZD3, FZD5, DVL3, FRAT2, and CK2A2 were validated as
direct targets of the miR-29 family. These data identify the
miR-29 family as microRNAs acting across development and
progression of OA. They are regulated by factors which are
important in OA and impact on relevant signalling pathways.
Key messages
& Expression of the miR-29 family is regulated in cartilage
during osteoarthritis.
& SOX9 represses expression of the miR-29 family in
chondrocytes.
& The miR-29 family is regulated by TGF-β1 and IL-1 in
chondrocytes.
& The miR-29 family negatively regulates Smad, NFκB,
and canonical Wnt signalling.
& Several Wnt-related genes are direct targets of the miR-29
family.
Keywords MicroRNA .Osteoarthritis . Sry-related box 9 .
Chondrocyte .Wnt pathway
Introduction
MicroRNAs (miRNAs) are short endogenous non-protein-
coding RNAmolecules, typically 19–25 nucleotides in length
[1]. They mediate the post-transcriptional regulation of
protein-coding genes by binding to the 3’ untranslated region
(3’ UTR) of target mRNAs leading to translational inhibition
or mRNA degradation, depending on the degree of sequence
complementarity. MicroRNAs can be master regulators of
gene expression and influence virtually all cell activities and
events [2]. As of January 2015, a total of 1881 precursors and
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2588 mature human miRNAs have been annotated in
miRBase release 21.0 [3]. Their function and regulation, how-
ever, are still only poorly understood.
Osteoarthritis (OA) is a degenerative joint disease
characterised by degradation of articular cartilage, thickening
of subchondral bone and osteophyte formation. The aetiology
of OA is complex with a number of factors contributing to the
disease: genetic, environmental, developmental, biochemical
and biomechanical [4]. Estimates are that over 10 % of the
world population above 60 years old have OA, with a large
socioeconomic burden [5]. There are no effective disease-
modifying drugs to treat OA, and drugs that relieve pain are
often insufficient, with joint replacement offered to patients at
end-stage disease. Increasing age and obesity are major risk
factors for OA, and changing population demographics sug-
gests that the burden of disease will rise [4].
Recent evidence reveals miRNAs as prominent modulators
of OA pathogenesis. MicroRNA-140, originally identified as
a cartilage- and skeletal-restricted miRNA in zebrafish [6] and
mouse development [7], is currently the best described
miRNA in cartilaginous tissue. Universal knockout of miR-
140 lead to mild craniofacial deformities and dwarfism [8, 9].
These mice prematurely develop OA-like changes with age
and are more susceptible to OA in the ‘destabilisation of the
medial meniscus’ (DMM)model, whilst transgenic mice over-
expressing miR-140 in cartilage were resistant to antigen-
induced arthritis. A number of miRNAs are reported to be
altered in expression between late-stage OA cartilage and their
normal articular counterpart and/or in cartilage development
[10]. Since miR-140 has such a key role in cartilage homeo-
stasis and osteoarthritis, it is likely that other miRNAs will
show similar function as this is explored.
Sry-related box 9 (Sox9) is a transcription factor andmaster
regulator of cartilage formation, required for multiple steps in
the differentiation of chondrocytes [11]. It regulates expres-
sion of both type II collagen and proteoglycan, markers of the
chondrocyte phenotype [12]. Several miRNAs are regulated
by Sox9 (e.g. miR-140 and miR-455) [13–15] or regulate
Sox9 expression (e.g. miR-675 and miR-145) [16, 17].
We performed miRNA and mRNA profiling in total RNA
purified from whole mouse knee joints at early time points
after DMM surgery to identify important miRNAs in the de-
velopment of OA. Among these modulated miRNAs, the ex-
pression of miR-29b-3p, a member of miR-29 family, was
increased at 1 day post-surgery when it was regulated in the
opposite direction to its potential targets. The miR-29 family
in human and mouse consists of miR-29a, miR-29b (b1 and
b2 which are identical mature miRNAs) and miR-29c, with
the mature microRNAs differing only in two or three bases.
The family is encoded at two human genomic loci on chro-
mosome 1 (encoding a primary transcript for miR-29a and
miR-29b1) and chromosome 7 (encoding a primary transcript
for miR-29b2 and miR-29c). The family is known to regulate
a number of extracellular matrix genes, as well as regulatory
targets [18].
Hence, we investigated the expression of the miR-29 fam-
ily in a number of models relevant to cartilage and OA and
their regulation and function in chondrocytes.
Materials and methods
Destabilization of the medial meniscus (DMM) model
C57BL/6 mice were purchased from Harlan, UK. Animal ex-
periments were performed following ethical and statutory ap-
proval in accordance with local policy. Mice were maintained
at 21 °C in standard, individually ventilated cages holding 3–6
mice per cage. Ten-week-old malemice were anaesthetized by
inhalation of Isoflurane (3 % induction and 1.5–2 % mainte-
nance) in 1.5–2 L/min oxygen. All animals received a subcu-
taneous injection of Vetergesic (Alstoe Animal Heath Ltd)
post-surgery. The mice were fully mobile within 4–5 min fol-
lowing withdrawal of Isoflurane. Destabilization of the medial
meniscus (DMM) was performed as previously described [19]
with capsulotomy only as sham [20]. The contralateral (left)
knees were non-operated controls. Knees were harvested at 1,
3 and 7 days post-surgery.
Patient samples Femoral head and knee cartilage were ob-
tained from osteoarthritis (hip OA (HOA) age 61–89 years,
four female and two male; knee OA (KOA) age 55–71 years,
two female and three male) and trauma (NOF (neck of femur),
age 71–92 years, four female and two male) patients undergo-
ing total joint replacement surgery at the Norfolk and Norwich
University Hospital. OAwas diagnosed using clinical history
and examination, coupled with X-ray findings; confirmation
of gross pathology was made at time of joint removal. Fracture
patients had no known history of joint disease, and their car-
tilage was free of lesions. This study was performed with
Ethical Committee approval, and all patients provided in-
formed consent.
Cell culture SW1353 chondrosarcoma cells were from the
American Type Culture Collection and cultured in
Dulbecco’s modified Eagle’s medium (DMEM, Life
Technologies) containing 10 % (v/v) fetal bovine serum
(Sigma), 2 mM glutamine, 100 IU/ml penicillin and
100 μg/ml streptomycin as described [14]. Primary human
articular chondrocytes (HACs) were isolated from cartilage
of osteoarthritis patients as described [21] and cultured as
above. DF1 cells (a gift from Prof. Andrea Münsterberg,
University of East Anglia, UK) are spontaneously trans-
formed chicken embryo fibroblast cells [22] and were cultured
as above. Human mesenchymal stem cells (hMSC) were re-
suspended in chondrogenic culture medium consisting of high
glucose Dulbecco’s modified Eagle’s medium containing
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100 μg/ml sodium pyruvate (Lonza), 10 ng/ml TGF-β3
(Peprotech), 100 nM dexamethasone, 1× ITS-1 premix,
40 μg/ml proline and 25 μg/ml ascorbate-2-phosphate (all
from Sigma-Aldrich, Poole, UK). About 5× 105 hMSC in
100 μl medium were pipetted onto 6.5-mm diameter,
0.4-μm pore size polycarbonate Transwell filters (Merck
Millipore), centrifuged in a 24-well plate (200 g, 5 min), then
0.5 ml of chondrogenic medium was added to the lower well
as described [15]. Media were replaced every 2 or 3 days up to
14 days. Induction of the murine chondrogenic cell line,
ATDC5 was as described in [14]. For micromass culture, pri-
mary HACs were grown in monolayer culture until passage
two. Confluent cells were then trypsinised and resuspended at
a density of 2×107 cells/ml in DMEM high glucose, with
GlutaMAX (Life Technologies), containing 10 % (v/v) fetal
bovine serum, 100 IU/ml penicillin and 100 μg/ml streptomy-
cin (growth medium). Micromass was obtained by pipetting
20 ul cell suspension into individual wells of 24-well plates
and incubating for 3 h to attach. One ml growth medium was
then added, and the micromass was incubated for 24 h.
Growth medium was then replaced with DMEM high
glucose medium containing 1× insulin-transferrin-
selenium (Life Technologies), with or without cytokines
or growth factors for 48 h. Inhibition of NFκB was
achieved using JSH-23 (Calbiochem) and inhibition of
p38 MAP kinase used SB203580 (Sigma) at the con-
centrations shown.
Mouse femoral head cartilage wounding assay The mouse
femoral head cartilage wounding assay was as described [23].
Tissue was harvested into 500 μl Trizol (Life Technologies) at
the time points: 0, 1, 3, 6, 12, 24 and 48 h and stored at −80 °C.
RNA isolation and qRT-PCR Trizol reagent was used to
isolate total RNA from cultured cells according to manufac-
turer’s instructions; a further purification step using the
mirVana miRNA Isolation Kit (Life Technologies) was per-
formed for total RNA from cartilage. The miRCURY LNA™
Universal cDNA synthesis kit (Exiqon, Denmark) and
miRNA-specific LNA™ primers (Exiqon) were used for
quantification of mature miRNA transcripts by qRT-PCR.
Data were normalized to U6 as the housekeeping gene. For
mRNA, SuperScript III RT (Life Technologies) using 1 μg of
total RNA (Dnase I treated) with random hexamers (Life
Technologies) was used with data normalised to expression
of 18S ribosomal RNA. Primer sequences are listed in
Supplementary Table 1. Both miRNA and mRNA relative
quantifications were calculated using the ΔΔCT method.
Fluorescence for each cycle was analysed by the real-time
PCR 7500 system (Applied Biosystems).
Microarray analyses FormiRNA analysis in the DMMmod-
el, for each time point, total RNA samples from four animals
were pooled for array. MicroRNA microarray was performed
by Exiqon (Denmark). The raw data were background
corrected, normalized by the locally weighted scatterplot
smoothing (LOWESS) algorithm and summarized at the
log2-scale using the program R. Profiling of mRNA used the
Illumina Human HT12v4 platform or Mouse WG-6 platform
(Source Bioscience). Data were imported to R Studios and
analysed using the Bioconductor packages. Expression values
were normalized using Robust Multichip Average (RMA)
methodology. The 3’ UTR sequences of mRNAs were
imported from Ensembl into R. The miRNA seed sites were
identified using the BioStrings package. Frequency of
mRNAs which are targets of a miRNA at each fold change
value was calculated as the ratio of mRNA containing a seed
site to the total number of mRNAs modulated with that fold
change.
Transient tranfection The 3’ UTR of mRNAs containing the
predicted binding site of miR-29-3p were subcloned into
pmirGLO (Promega), using QuikChange (Agilent) to intro-
duce mutations. Constructs were sequence verified. DF1 cells
were seeded into a 96-well plate at 3.75×104 cells/cm2 over-
night and transiently transfected with 100 ng reporter plasmid,
50 nM miRNA mimic, inhibitor or control using
Lipofectamine 2000 according to manufacturer’s instructions
(Life Technologies) and incubated for 24 or 48 h. Cell lysates
were assayed for luciferase using the Dual Luciferase
Reporter Assay Kit (Promega), read with an EnVision 2103
Multilabel plate reader (Perkin Elmer). Relative luciferase ac-
tivity was the ratio of firefly luciferase to Renilla luciferase
activity. Signalling pathways were measured using
p(CAGA)12-luc (Smad2/3) [24]; κB-luc (NFκB) [25] and
TOPFlash (canonical Wnt) [26]. One hundred nanogram of
the plasmid and 10 ng of constitutive Renilla plasmid were co-
transfected into SW1353 cells with 50 nM miR-29 mimic,
inhibitor or control. After serum starvation for 24 h, cells were
treated with recombinant human TGFβ1 (4 ng/ml), IL-1β
(5 ng/ml), or Wnt3a (100 ng/ml) (R&D Systems) for 6 h.
For promoter assays, 100 ng of plasmid containing the miR-
29a/b1 promoter [27] was co-transfected with 100 ng of hu-
man SOX9 expression plasmid (a gift of Dr. Simon
Tew, University of Liverpool, UK, [28]) or control plas-
mid, and 10 ng of Renilla plasmid in SW1353 cells for
24 h. Knockdown of SOX9 used 100 nM SOX9 small
interfering RNA (siRNA) (Dharmacon) for 48 h. For
loss- or gain-of-function experiments, primary HACs
were plated at 2.5 × 105 cells per well of a 6-well plate
overnight. Cells were transfected for 6 h in serum- and
antibiotic-free DMEM using Lipofectamine 2000
(Invitrogen), miR-29b-3p mimic at 30 nM (Qiagen),
miR-29b-3p inhibitor at 50 nM (Qiagen), or non-
targeting controls (All Stars at 30 nM (Qiagen),
miScript Inhibitor control at 50 nM (Qiagen)). Media
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were replaced with complete medium for a further 48 h
prior to harvest.
Statistical analysis Data were analysed using Student’s t test
to compare between two samples or one-way ANOVA with
post hoc Tukey’s test to compare between multiple samples
using GraphPad Prism version 5.
Results
Expression of the microRNA-29 family in osteoarthritis
In order to identify the specific miRNAs involved in
osteoarthritis, we explored the expression of miRNAs
early after surgery in a murine model of joint
destabilisation. This was reinforced by measuring ex-
pression in a murine model of cartilage injury and in
human cartilage from end-stage OA.
In the murine DMM model, total RNA was isolated from
whole joints at day 1, 3 and 7 post-surgery and pools of four
replicates subjected to miRNA and mRNA microarray.
Comparing the operated knee with contralateral control
showed two miRNAs increased by DMM surgery >1.5-
fold at day 1 (miR-144-3p and miR-29b-3p) and two
miRNAs at day 3 (miR-370-5p and miR-21-5p).
Greater than 30 miRNAs altered expression >1.5-fold
at day 7 (Supplementary Table 2). Expression of
mRNAs showed the same pattern of greater change at
day 7. Correlation analysis between miRNA and their
putative mRNA targets showed that for the four
miRNAs with altered expression at day 1 or 3 post-
surgery, there was an inverse correlation only between
miR-29b-3p and its putative targets (genes containing
either 6mer or 7mer-m8 seed sites). Of the genes whose
expression was decreased when expression of the
miRNA was increased, there was an enrichment of po-
tential miR-29-3p targets identified and vice versa
(Fig. 1a). Since miRNAs function by decreasing their
target mRNAs, this suggests functional involvement of
this miRNA at the early stages of the DMM model.
Expression of miR-29b-3p was validated by qRT-PCR
in the knee undergoing both DMM and sham surgery
compared to un-operated control at day 1 post-surgery
(Fig. 1a). MicroRNA-29b is a member of the miR-29
family, along with miR-29a and 29c, which are encoded
at two genomic loci and share a seed sequence (Fig. 1b)
[29]; all were included in downstream investigations
since their seed sites are identical.
Cartilage injury can precede OA [30], and a murine carti-
lage injury model (hip avulsion) was shown to display similar
gene expression patterns to the DMM model [23].
Measurement of the miR-29-3p family in this model showed
a significant increase in expression at 12–48 h post-
explantation of cartilage, with a trend to increase for miR-
29a and c at 6 h (Fig. 1c).
Expression of the miR-29 family was measured in
human articular cartilage from hip replacement surgery
for OA or fracture to the neck-of-femur (NOF, control).
The expression of miR-29a-3p, miR-29b-3p and miR-
29c-3p was increased in osteoarthritis compared to
NOF (Fig. 1d).
Expression of the microRNA-29 family in chondrocyte
differentiation and regulation by SOX9
Since the replay of chondrogenesis and altered cell differenti-
ation can contribute to OA [31], expression of the miR-29
family was investigated in appropriate models. In human
MSC differentiation to form cartilage discs over 14 days, the
miR-29 family decreased in expression to 7 days, returning to
starting levels by 14 days (Fig. 2a). This pattern was inversely
correlated with SOX9 expression (Fig. 2a). A similar pattern
was seen in the murine ATDC5 chondrogenesis model over
42 days, with decrease to 21 days, returning to baseline by
42 days (data not shown). In the human model, the expression
profile of both miRNA and mRNAwas measured using array
as described [15]. An enrichment of potential miR-29 targets
was identified in upregulated genes, when expression of the
miR-29 family was low (data not shown) suggesting function-
al involvement of the miR-29 family.
Expression of the miR-29 family was also measured across
dedifferentiation of human articular chondrocytes upon serial
passage in monolayer culture. Expression decreased with sub-
culture (Fig. 2b) with a similar pattern to COL2A1 [32].
Sox9 is a critical transcription factor regulating chondro-
cyte differentiation [33]. From data above, we hypothesised
that SOX9 was a negative regulator of miR-29 expression in
chondrocytes. Overexpression of SOX9 in SW1353 cells
leads to a decrease in expression of the miR-29 family, whilst
knockdown of SOX9 increased their expression (Fig. 2c). The
2 kb region upstream of the miR-29a/b1 transcription start site
contains five putative binding sites for SOX9 (data not
shown). Co-transfection of this region in a promoter-reporter
plasmid with a SOX9 expression construct showed a dose-
dependent decrease in luciferase activity with increasing
SOX9 expression (Fig. 2d).
Factors controlling expression of the miR-29 family
Having shown the miR-29 family to be expressed in
models of OA and cartilage development and regulated
directly by Sox9, we explored the regulation of the
miR-29 family in chondrocytes by cytokines and growth
factors known to be important in cartilage homeostasis
and OA.
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Transforming growth factor beta (TGFβ) is a key factor in
OA and has been shown to regulate miR-29 expression in
fibrosis [18]. The impact of TGFβ1 on miR-29 expression
in chondrocytes was investigated in monolayer culture and
in three-dimensional micromass culture. Figure 3a shows that
in monolayer culture, the primary and precursor transcripts of
miR-29a and miR-29b1 were not regulated by TGFβ1,
though the mature miR-29a-3p was still reduced. Expression
Fig. 1 Identification of the miR-29 family in osteoarthritis. a
MicroRNA-29b-3pwasmeasured by qRT-PCR fromRNA obtained from
mouse knee joints at 24 h post-surgery after ‘destabilisation of the medial
meniscus’ (mean ± SEM, ANOVA, n= 3). The frequency of predicted
miR-29 targets in mRNAwith seed sites of either 6mer or 7mer m8 was
calculated (see Material and Methods) across fold changes of gene ex-
pression. b In man, the miR-29 family is expressed from two loci, with
the primary miR-29a/b1 on chromosome 7 (the last intron of the primary
transcript GenBank accession EU154353) and primary miR-29b2/c on
chromosome 1 (the last exon of the primary transcript GenBank accession
numbers EU154351 and EU154352) [29]; mature sequences of miR-29a,
b and c (3p) have identical seed sequences. c The miR-29 family was
measured by qRT-PCR in the murine hip avulsion injury model over 48 h
post-injury (mean ± SEM, ANOVA, n= 6). Empty bars, miR-29a; grey
bars, miR-29b and black bars, miR-29c. d The miR-29 family was
measured by qRT-PCR in cartilage from hip osteoarthritis (HOA, filled
bars) patients compared to fracture (NOF, empty bars) controls
(qRT-PCR, mean ± SEM, Student’s t test, n= 6). Data were normalised
to U6 RNA expression *p < 0.05; **p< 0.01; ***p< 0.001
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of primary miR-29b2/c, the precursor and mature miR-29b
and miR-29c were significantly repressed by TGFβ1 in
monolayer culture. In micromass culture, the converse was
true (Fig. 3b), with no effect (or an increase) on primary
miR-29b2/c or precursors for miR-29b2 and miR-29c, though
the mature miR-29c-3p was still reduced. Expression of pri-
mary miR-29a/b1 and the precursor and mature miR-29a-3p
and miR-29b-3p were significantly repressed by TGFβ1 in
micromass culture. This suggests not just regulation of tran-
scription, but also at the level of maturation of the precursor to
mature form of the microRNA by TGFβ1. In a transient trans-
fection experiment, the miR-29a/b1 promoter is repressed by
TGFβ1 in SW1353 cells (Fig. 3c).
Interleukin-1 (IL-1) is a catabolic cytokine, implicat-
ed in destruction of cartilage in OA [34]. In monolayer
culture, IL-1 increased expression of the primary miR-
29a/b1 transcript, precursors of miR-29a and miR-29b1,
and the mature miR-29a-3p and miR-29b-3p (Fig. 4a).
No significant induction of pri-miR-29b2/c or pre-miR-
29b2 or pre-miR-29c was seen, though IL-1 increased
the mature miR-29c-3p (Fig. 4a). In micromass culture,
IL-1 increased expression of all primary and precursor
transcripts and the mature miR-29 family (Fig. 4b).
Interestingly, the miR-29a/b1 promoter was repressed
by IL-1, and this was rescued by inhibiting NFκB with
JSH-23 (Fig. 4c). Similarly, the induction of miR-29
precursors was also augmented by inhibiting NFκB
(Fig. 4c), suggesting that NFκB acts as a negative reg-
ulator of miR-29 expression. LPS, another factor which
induces NFκB, decreased the expression of pri- and
pre-miR-29a and miR-29b1 at an early time point
(4 h), with the mature miR-29a-3p and miR-29b-3p
reduced at 24 h (Fig. 4d). A similar pattern was seen
for miR-29b2 and miR-29c, though this did not
reach significance (data not shown). The miR-29a/b1
promoter was regulated by LPS in an identical manner
to IL-1 (data not shown), with suppression rescued by
an NFκB inhibitor. A p38 inhibitor (SB203580) blocked
induction of the miR-29 family by IL-1, showing that
this was, at least in part, dependent on the p38 pathway
(Fig. 4c).
The Wnt pathway has also been implicated in OA [35].
However, microRNA-29 expression was not modulated by
Wnt3a with no effect on the miR-29a/b1 promoter (data
not shown).
There is no simple relationship between regulation of
SOX9 by these factors and that of miR-29. For example, in
micromass, TGFβ1 decreases SOX9 by 2.0-fold (Fig. 3b), IL-
1 decreases SOX9 by 3.2-fold (Fig. 4b) and LPS increases
SOX9 by 2.0-fold at 4 h, 2.15-fold at 24 h and decreases it
by 3.5-fold at 48 h (Fig. 4d). Whilst this shows a correlation
with miR-29 expression for IL-1, this is not true for TGFβ1
and LPS. Wnt3a also decreases SOX9 expression by
approximately threefold, yet has no effect on miR-29 expres-
sion (data not shown).
The miR-29 family regulates key signalling pathways
In order to probe intracellular signalling pathways which are
involved in OA, constructs were used in which luciferase ex-
pression was driven by specific factors: p(CAGA)12-luc
which responds to Smad2/3/4 as a readout of TGFβ1 activa-
tion; κB-luc which responds to NFκB as a readout of IL-1 or
LPS activation; TOPFlash which responds to canonical Wnt
signalling. Thesewere reinforced bymeasuring the expression
of genes which respond to these agonists: ADAMTS4 as a
TGFβ1-inducible gene; MMP3 as an IL-1-inducible gene
and Axin2 as a Wnt-inducible gene.
Since TGFβ1 regulated expression of the miR-29 family,
we measured the Smad 2/3/4 pathway using transient trans-
fection of the p(CAGA)12-luc Smad-responsive plasmid.
Figure 5a shows that a miR-29b-3p mimic repressed Smad
signalling, inhibiting the TGFβ1 induction of the construct;
conversely, an inhibitor of miR-29b-3p augmented TGFβ1
induction. Figure 5a shows that TGFβ1-induced ADAMTS4
expression was repressed by transfection of miR-29 family
mimics, verifying the effect on an endogenous gene.
Similarly, miR-29-3p repressed NFκB signalling,
inhibiting IL-1 induction of a κB-luc construct, whilst the
inhibitor of miR-29b-3p augmented the response
(Fig. 5b). The MMP3 gene, which is responsive to
NFκB, as well as other transcription factors, was in-
duced by IL-1 and significantly repressed by miR-29
family mimics (Fig. 5b).
Fig. 2 Expression of the miR-29 family in chondrocyte differentiation.
Expression of the miR-29 family and SOX9 was measured by qRT-PCR
from RNA a obtained from human mesenchymal stem cells induced
through chondrogenesis to form cartilage discs at day 0, 3, 7 and 14
(mean ± SEM, ANOVA, n = 6); empty bars, miR-29a; grey bars, miR-
29b; black bars, miR-29c. b purified from osteoarthritic knee cartilage
tissue (Ca) or isolated from chondrocytes in monolayer culture at P0, P1,
P2 and P3 (mean ± SEM, ANOVA, n = 4 for cartilage and n = 8 for
cultured chondrocytes). Data were normalised to U6 RNA expression.
Empty bars, miR-29a; grey bars, miR-29b; black bars, miR-29c. c A
SOX9 expression vector or empty pcDNA3 vector (control), SOX9
siRNA or a non-targeting control (control) were transiently transfected
into SW1353 for 48 h. SOX9 was measured by qRT-PCR and normalised
to 18S rRNA expression (mean ± SEM, Student’s t test, n= 3 (overex-
pression), n= 5 (siRNA). Expression of the miR-29 family was measured
by qRT-PCR after overexpression or knockdown of SOX9; data were
normalised to U6 RNA expression (mean ± SEM, Student’s t test, n = 3
(overexpression), n= 4 (siRNA). Empty bars, control; filled bars, Sox9
overexpression or knockdown. d A primary miR-29a/b1 promoter-
reporter construct was transfected into SW1353 cells with the empty
pcDNA3 vector to equalise DNA transfected, luciferase activity was
measured at 24 h and data were normalised to Renilla luciferase from a
co-transfected constitutive expression vector (mean ± SEM, ANOVA,
n= 6). *p< 0.05; **p< 0.01; ***p< 0.001. Data were normalised to U6
RNA expression
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Whilst miR-29 expression is not regulated by Wnt3a, we
measured the impact of miR-29 on canonical Wnt signalling,
using the TOPFlash construct. The miR-29-3p mimic
repressed Wnt3a induction of this construct (with no effect
on the control FOPFlash), whilst it was augmented by the
miR-29b-3p inhibitor (Fig. 5c). Wnt3-induced Axin2 expres-
sion was significantly, though minimally, repressed by miR-29
family mimics (Fig. 5c).
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The action of the miR-29 family in articular chondrocytes
We performed gain-of-function and loss-of-function experi-
ments to identify miR-29 targets in primary HACs. Cells were
transfected with miR-29b-3p mimics, inhibitors or non-
targeting controls, and the transcriptome analysed on
Illumina microarray. Our previous research [36] showed that
miRNA targets are enriched amongst genes which are de-
creased upon overexpression of the miRNA, increased on in-
hibition of the miRNA and contain seed sites for the miRNA.
This intersection contained a number of known direct targets
for miR-29 (e.g. COL1A1 and COL3A1), see Supplementary
Table 3. Pathway analysis (DAVID) highlighted the Wnt sig-
nalling pathway, including DVL3, (Dishevelled 3);
CSNK2A2, (casein kinase 2 alpha 2 polypeptide); FRAT2,
(Frequently Rearranged In Advanced T-Cell Lymphomas 2,
a GSK-3 binding protein); FZD3, (Frizzled family receptor 3)
and FZD5, (Frizzled family receptor 5). The 3’ UTR of all
these genes was cloned into a luciferase reporter and
co-transfection of the miR-29-3p mimics resulted in sig-
nificant repression of luciferase expression (Fig. 6a).
Mutation of miR-29 seed sites (1–5 sites, depending
Fig. 3 Regulation of the miR-29 family by TGFβ1. Human primary
articular chondrocytes were grown either in monolayer (a) or
micromass (b) culture (as Materials and Methods). In monolayer, cells
were transferred to 0.5 % (v/v) FCS-containing medium overnight before
stimulation with TGFβ1 (4 ng/ml) or vehicle for 24 h. In micromass, cells
were stimulated for 48 h with TGFβ1 (10 ng/ml) or vehicle in 10 % (v/v)
FCS-containing medium. Expression of the primary miR-29a/b1, -29b2/
c, precursor miR-29a, -29b1, -29b2, -29c and the mature miR-29a, b, c or
SOX9 were measured by qRT-PCR. Primers from two regions of the
primary miRNA were used as shown (exon 1 and exon 4). Data were
normalized to 18S rRNA expression for primary and precursor miRNA
and to U6 expression for mature miR-29 and then vehicle control
(mean ± SEM, ANOVA, n= 3). Empty bars, pri-miR29a/b1; light grey
bars, pri-miR29-b2/c; dark grey bars, pre-miR-29; black bars, mature
miR-29; horizontal line at 1, vehicle control. A primary miR-29a/b1
promoter-reporter construct or empty pGL4 vector (c) were transfected
into SW1353 cells; after serum starvation for 24 h, cells were stimulated
with TGFβ1 (4 ng/ml) or vehicle for a further 6 h before measuring
luciferase activity. Data were normalised to Renilla luciferase from a
co-transfected constitutive expression vector (mean ± SEM, ANOVA,
n= 6). *p < 0.05; **p< 0.01; ***p< 0.001
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Fig. 4 Regulation of the miR-29 family by interleukin-1 and LPS. Human
primary articular chondrocytes were grown either in monolayer (a) or
micromass (b) culture (as Methods). In monolayer, cells were transferred
to 0.5% (v/v) FCS-containingmedium overnight before stimulationwith IL-
1β (5 ng/ml) or vehicle for 24 h. Inmicromass, cells were stimulated for 48 h
with IL-1β (10 ng/ml) or vehicle in 10 % (v/v) FCS-containing medium.
Expression of the primarymiR-29a/b1, -29b2/c, precursor miR-29a, -29b1, -
29b2, -29c and the mature miR-29a, b, c or SOX9 were measured by qRT-
PCR. Primers from two regions of the primary miRNAwere used as shown
(exon 1 and exon 4). Data were normalized to 18S rRNA expression for
primary and precursor miRNA and to U6 expression for mature miR-29 and
then vehicle control (mean ± SEM, ANOVA, n=3). Empty bars, pri-miR-
29a/b1; light grey bars, pri-miR-29b2/c; dark grey bars, pre-miR-29; black
bars, mature miR-29, horizontal line at 1, vehicle control. cA primary miR-
29a/b1 promoter-reporter construct was transfected into SW1353 cells; after
serum starvation for 24 h, cells were stimulated with IL-1β (5 ng/ml), +/− an
NFκB inhibitor JSH-23 (10 μM) or vehicle for a further 6 h before measur-
ing luciferase activity. Data were normalised to Renilla luciferase from a co-
transfected constitutive expression vector (mean ± SEM, ANOVA, n=6).
Human primary articular chondrocytes in monolayer were serum starved for
24 h and stimulated with IL-1β (5 ng/ml) +/− an NFκB inhibitor JSH-23
(10μM) or a p38MAPK inhibitor SB203580 (10μM) or vehicle control for
6 h. Expression of pre-miR-29a and b1 were measured by qRT-PCR and
normalized to 18S rRNA (mean ± SEM,ANOVA, n=3). dHuman primary
articular chondrocytes were cultured in micromass as (b) and stimulated
across 48 h with LPS (1 μg/ml) or vehicle in 10 % (v/v) FCS-containing
medium (F); primary miR-29a/b1, precursor miR-29a, -29b1 and the mature
miR-29a, b were measured as (b) (mean ± SEM,ANOVA, n=3). *p<0.05;
**p<0.01; ***p<0.001. Empty bars, pri-miR-29a/b1; dark grey bars, pre-
miR-29; black bars, mature miR-29; horizontal line at 1, vehicle control
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on gene), abolished this repression, demonstrating that
all these genes are direct targets of the miR-29 family
(Fig. 6a). Interestingly, Axin2 expression, readout of
canonical Wnt signalling, was decreased in hip OA car-
tilage compared to NOF (Fig. 6b) where miR-29 expres-
sion was increased (Fig. 1d).
Discussion
This study was driven by expression profiling miRNAs at
early time points post-surgery in the murine DMM model of
OA. Using whole knee joint RNA, only two miRNA altered
significantly in expression 24 h after surgery and of these,
miR-29b-3p was inversely correlated with expression of its
putative targets. Further, expression of the miR-29 family
was significantly increased in human cartilage from end-
stage OA. Expression of miR-140-5p is also increased in
OA in these samples, despite published data showing the con-
verse and the increased susceptibility to OA in the miR-140
null mouse [8, 14]. This may reflect stage of the disease and/or
the control tissue (see, e.g. [14]). Guerit et al. [37] show no
difference in expression of miR-29a in OA compared to
healthy cartilage, but the source of the tissue is uncertain.
Since expression of the miR-29 family is increased immedi-
ately post-surgery in the DMM model and is increased upon
hip cartilage avulsion, this may be a response to injury, a
known phenomenon for miRNAs in several areas of physiol-
ogy and pathology, including cartilage, e.g. [38, 39]. It is moot
if the same mechanism(s) increase expression of the miR-29
family in cartilage from end-stage human OA.
The miR-29 family was regulated in both human and mouse
models of cartilage development though decreased expression
of the miR-29 family in models of chondrogenesis has been
described before [37, 40, 41]. Expression of the miR-29 family
was highest in human articular cartilage tissue, decreasing with
cell passage in monolayer culture. This is opposite to the ex-
pression of COL1A1, a gene which it is known to regulate.
Since expression of the miR-29 family in the MSC chon-
drogenesis model was inversely correlated with expression of
SOX9, we examined the role of SOX9 in the regulation of
miR-29 expression. This showed SOX9 as a negative regula-
tor of miR-29 expression, and we further demonstrated that
this was via the promoter for the miR-29a/b1 cluster. This
Fig. 5 Regulation of intracellular
signaling pathways by miR-29b-
3p. SW1353 cells were
transfected with (CAGA)12-luc
(a), κB-luc (b) or TOPFlash and
FOPFlash vectors (c) and co-
transfected with either 50 nM
miR-29b-3p mimics, inhibitors or
non-targetting controls. After
24 h, cells were serum starved and
treated with TGFβ1 (4 ng/ml) (a),
IL-1β (5 ng/ml) (b) or Wnt3a
(100 ng/ml) (c) for 6 h prior to
assay for luciferase activity. Data
were normalized to Renilla
luciferase (mean ± SEM,
Student’s t test, n = 6). Human
primary chondrocytes were
transfected with miR-29-3p
family mimics or non-targeting
control (50 nM) for 24 h, after
culture in low serum (0.5 % v/v
FCS) for 24 h, cells were
stimulated with TGFβ1 (4 ng/ml)
(a), IL-1β (5 ng/ml) (b) or Wnt3a
(100 ng/ml) (c) for 24 h. Gene
expression (ADAMTS4 a;
MMP3 b; Axin2 c) was measured
by qRT-PCR and normalized to
18S rRNA (mean ± SEM,
ANOVA, n = 3). *p< 0.05;
**p< 0.01; ***p< 0.001. Empty
bars, control; black bars,
treatment
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agrees with recent data from Guerit et al., with miR-29a de-
creasing across 21 days in their model of chondrogenesis and
SOX9 increasing across 3 days and decreasing thereafter.
They showed SOX9 negatively regulating miR-29 which
allowed an increase in FOXO3A leading to the differentiation
of MSC into chondrocytes [37]. Our data also show that there
is no direct relationship between SOX9 and growth factor
regulating the miR-29 family, in agreement with studies show-
ing SOX9-dependent and independent regulation of gene ex-
pression by growth factors [42].
Recent research is unravelling the intracellular signalling
pathways which underlie osteoarthritis and their interaction
(e.g. [43]). It is clear that several pathways are involved in
cartilage homeostasis and osteoarthritis and that their
interaction is key to their phenotypic outcome [44,
45]. The NFκB pathway has a catabolic role in cartilage
destruction, but pathways such at TGFβ and Wnt can
have positive or negative effects on the tissue [46]. We
pursued the relationship between these three factors and
the miR-29 family in primary HACs since the literature
suggests that this is cell-type specific.
TGFβ1 repressed expression of pri-miR-29b2/c and sub-
sequent pre-miR-29b2 and c in monolayer culture, with no
significant effect on the pri-miR-29a/b1 locus. Conversely,
in micromass culture TGFβ1 repressed the pri-miR-29a/b1
locus, but not the pri-miR-29b2/c locus. There is a difference
in culture conditions (e.g. level of FCS, time) between mono-
layer and micromass which may impact on this, but it is im-
portant to note that TGFβ1 effects in the three dimensional
system are different. However, in both cases, all three mature
Fig. 6 The miR-29 family
directly targets members of the
Wnt pathway. a The 3’ UTR of
FZD3, FZD5, DVL3, FRAT2 and
CSNK2A2 was subcloned
downstream of luciferase in the
pmiRGLO vector to create the
wild-type construct. All seed sites
of the miR-29 family were altered
to non-binding sequences
(number of sites shown) to create
mutant constructs. Constructs
were transfected into DF1
fibroblasts with miR-29 mimics
or non-targeting controls (50 nM)
and assayed for luciferase activity
after 24 h. Data were normalised
to Renilla luciferase and then the
non-targeting control (mean ±
SEM, ANOVA, n= 6). Striped
bars, control; empty bars, miR-
29a; grey bars, miR-29b; black
bars, miR-29c. b Expression of
axin2 was measured in cartilage
from hip osteoarthritis (OA)
patients compared to fracture
(NOF) controls (qRT-PCR, mean
± SEM, Student’s t test, n = 12)
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members of the miR-29 family were repressed. TGFβ1 is
known to repress the miR-29 family in a number of cell types
(e.g. [18, 47], and this is the same in primary chondrocytes.
Whilst this has been shown to be Smad3-dependent in, e.g.
renal fibrosis [47], and our data agree with an effect on the
promoter, it may be that processing from pre-miRNA to ma-
ture miRNA is the major determinant in their final expression
controlled by TGFβ, rather than transcription. Previous re-
ports have shown that a number of mature miRNA are in-
duced by TGFβ1 at the level of DROSHA-mediated
miRNA maturation [48], but no mechanism for TGFβ1 re-
pression of miRNA maturation has been described. However,
regulation of miRNA biogenesis by a number of factors has
been described at every level [49]. MicroRNA-29 also re-
presses TGFβ1-induced Smad signalling shown through the
(CAGA)12-luc construct or endogenous TGFβ1 responsive
genes in primary chondrocytes. This gives a feed forward loop
where TGFβ1 reduces levels of miR-29 which are repressing
the Smad pathway and therefore allows a greater increase in
Smad-dependent gene regulation.
The NFκB pathway is repressed by miR-29 though there
are opposing effects on miR-29 expression regulated by either
IL-1 or LPS. Whilst LPS is not directly involved in OA, it is a
TLR4 agonist which induces NFκB, and this pathway is
strongly implicated in disease (e.g. [50, 51]). IL-1 induces
the miR-29 family in a p38MAPK-dependent manner, though
the NFκB pathway represses miR-29 expression. This latter
can be seen through LPS repression of miR-29 expression, but
also an increased expression of miR-29 upon treatment with
an NFκB inhibitor, both pre-miR-29 and at the level of the pri-
miR-29a/b1 promoter. Expression of either p50, p65 or both
together repressed the pri-miR-29a/b1 promoter (data not
shown). In other cell lines, NFκB has been shown to act as
an inhibitor of miR-29 [52–54].
Whilst Wnt3a does not regulate miR-29 expression in pri-
mary HACs, miR-29 can repress canonical Wnt signalling, on
the TOPFlash construct and the Axin2 gene. Axin2 gene ex-
pression in osteoarthritic hip cartilage compared to a fracture
control is inversely correlated with that of miR-29 in the same
tissue. Negative regulation of canonical Wnt signalling by
miR-29 has been shown to be via targeting of DNMT3A
and 3B to demethylate WIF-1 in non-small-cell lung cancer
[55]. In human osteoblasts, miR-29 is induced by canonical
Wnt signalling and miR-29 potentiates Wnt signalling, dem-
onstrating the cell type-specific nature of miR-29 function [27,
56]. Interestingly, miR-29 gain- and loss-of-function microar-
ray experiments in primary HACs highlighted a number of
genes from the Wnt signalling pathway as potential targets
of miR-29 in articular chondrocytes. Several of these have
been validated, showing the functional capability of miR-29
on this pathway in cartilage. FZD3 and FZD5 are Wnt recep-
tors with DVL3 a downstream intracellular signalling mole-
cule in the Wnt pathway. FRAT2 is a GSK3 binding protein
and CSNK2A2 encodes a subunit of casein kinase 2 alpha [57,
58]. These are positive regulators of the Wnt pathway, and
targeting them is likely to suppress Wnt signalling, which is
the outcome of miR-29 action (Fig. 5).
These data show a complex role for the miR-29 family in
cartilage homeostasis and OA. Figure 7 shows the relation-
ships, we have identified amongst cytokines, growth factors
and signalling pathways with the miR-29 family. These are
not linear relationships, but rather result in complex feedback
mechanisms which wi l l regula te s ignal l ing in
chondrocytes during development and disease. This fig-
ure demonstrates that the miR-29 family adds an addi-
tional level of regulation across key pathways of carti-
lage homeostasis, and its dysregulation could either lead
or contribute to disease.
Fig. 7 A schematic of the role of
the miR-29 family in cartilage.
Data from this study have
identified a complex interplay
between the miR-29 family and
key signalling pathways which
regulate cartilage homeostasis.
The TGFβ, IL-1, and Wnt
pathways regulate and/or are
regulated by the miR-29 family
highlighting a nonlinear system,
with outcomes on the expression
of matrix or matrix-degrading
genes
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In summary, we have shown that the miR-29 family has a
role in osteoarthritis, including early disease. The miR-29
family is regulated by a number of factors known to be im-
portant in OA and has a functional impact on several relevant
signalling pathways. In these data, we have identified and
validated a number of genes as new direct targets of the
miR-29 family.
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